--U.S. FDA Delays: Sanofi is potentially exposed to any delays in reviews due to recently announced staff firings at the U.S. Food and Drug Administration. Its anti-inflammatory drug Dupixent was ...

ALA, its Divisions, Round Tables and Affiliates host many conferences, and in-person and online events to showcase cutting-edge developments in library advocacy, information literacy, and many other ...

Sanofi and Regeneron's Dupixent (dupilumab) has been approved by the FDA for the treatment of chronic spontaneous urticaria ...

The FDA had rejected the companies’ initial application in 2023, requesting additional data after the pharma firms reported ...

New Phase II data demonstrate amlitelimab’s efficacy in heterogeneous inflammatory asthma, as lunsekimig and itepekimab ...

Several states are reporting cases of measles, a highly contagious viral disease. Both children and adults can get measles.

(NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adults and adolescents aged 12 years and older with ...

The startup, affiliated with China-based antibody designer Helixon Therapeutics, is developing bispecific drugs aimed at ...

Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring by penning a new deal with ...